Compare BSRR & FHTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BSRR | FHTX |
|---|---|---|
| Founded | 1977 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 418.8M | 360.8M |
| IPO Year | 2001 | 2020 |
| Metric | BSRR | FHTX |
|---|---|---|
| Price | $36.25 | $5.74 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 7 |
| Target Price | ★ $38.50 | $11.71 |
| AVG Volume (30 Days) | 71.1K | ★ 116.0K |
| Earning Date | 05-05-2026 | 04-14-2026 |
| Dividend Yield | ★ 2.89% | N/A |
| EPS Growth | 10.28 | ★ 32.48 |
| EPS | ★ 3.11 | N/A |
| Revenue | N/A | ★ $22,602,000.00 |
| Revenue This Year | $11.74 | $40.91 |
| Revenue Next Year | $3.63 | $11.87 |
| P/E Ratio | $16.77 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $22.42 | $2.94 |
| 52 Week High | $38.60 | $6.95 |
| Indicator | BSRR | FHTX |
|---|---|---|
| Relative Strength Index (RSI) | 49.87 | 52.84 |
| Support Level | $36.00 | $4.44 |
| Resistance Level | $36.79 | $5.83 |
| Average True Range (ATR) | 1.42 | 0.34 |
| MACD | -0.22 | 0.01 |
| Stochastic Oscillator | 54.37 | 74.71 |
Sierra Bancorp is a California-based bank holding company, which offers a range of retail and commercial banking services. it offers a wide range of deposit products and services for individuals and businesses including checking accounts, savings accounts, money market demand accounts, time deposits, retirement accounts, and sweep accounts. The company's lending activities cover real estate, commercial (including small business), mortgage warehouse, agricultural and consumer loans, and also offers commercial construction loans and multifamily and agricultural credit facilities among other types of real estate loans.
Foghorn Therapeutics Inc is engaged in the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Its proprietary Gene Traffic Control platform gives an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing it to identify, validate, and potentially drug targets within the system. The company is developing FHD-286, a selective, allosteric ATPase inhibitor, and FHD-609, a protein degrader, to treat hematologic cancers and solid tumors.